An experimental treatment for Lou Gehrig’s disease won fast track and orphan drug designations from the Food and Drug Administration, potentially speeding the drug’s development by Neuraltus Pharmaceuticals Inc.
NP-001, the Palo Alto company’s treatment for amyotrophic lateral sclerosis, or ALS, received those designations last week, Neuraltus CEO Andrew Gengos told the San Francisco Business Times on Tuesday.
No comments:
Post a Comment